LILRB1 and neoplasm: Other preclinical trials targeting the macrophage “don’t eat me” signal have also yielded impressive results through the promotion of tumor cell phagocytosis by macrophages, such as those involving the inhibition of the MHC-I-LILRB1 axis, inhibition of the CD24-SIGLEC-10 axis, and CAR-M cellular immunotherapy (15–17).